Grace Lau, Head of Institute for Translational Research of HKSTP, said: “Our partnership with BIVF, provides early-stage startups and promising university spinoffs with vital support at the most critical stage of their long and challenging biotech innovation journey. We will maximise the GBA growth opportunities for high-potential tech talents and early-stage startups to ensure the region emerges as a global I&T powerhouse.”ĭr. As HKSTP marks our 20 th year of propelling success and innovation, our mission is to drive the growth of biotech to another level with world class leaders like BIVF. Albert Wong, CEO of HKSTP, said: “Hong Kong is now Asia’s largest and the world’s second largest fundraising hub for biotech.
#Fasttrack schedule version 3 plus
Incubatees can access one-on-one coaching and assessment to track key research milestones, while receiving expert guidance from HKSTP on commercialisation, manufacturing, scaling-up and marketing strategy to ensure successful innovation, plus vital funding opportunities and investment insight from BI.
#Fasttrack schedule version 3 full
Both local and global qualified startups in infectious diseases and immunology can apply to the incubation programme to access the full capabilities of the HKSTP ecosystem and BIVF’s extensive biotech funding network. This partnership between HKSTP and BIVF marks a key milestone to drive the Hong Kong’s biomedical technology development. In the last five years, the number of biotech companies at HKSTP have tripled from 50 to over 150, which has also synched with the Government’s strategic focus on biomedical technology with allocation of HK$10 billion to develop life and health technology as a key future growth sector for Hong Kong. HKSTP is dedicated to collaborating with sector leaders in building the strongest I&T eco-system to help startups via business development, mentorship and investment initiatives.
Hong Kong Science and Technology Parks Corporation (HKSTP) is partnering global research-driven biopharmaceutical leader, Boehringer Ingelheim Venture Fund Limited (BIVF) in a strategic co-incubation collaboration to promote and nurture startups on research and development for infectious diseases and immunology.
0 kommentar(er)
